Previous 10 | Next 10 |
Omeros (OMER) announces preliminary results from the Phase 1 clinical trial of its MASP-3 inhibitor OMS906.The trial is designed as a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics ((PK)) and pharmacodynamics ((PD)) of intravenous ...
-- Results show good safety and PK/PD profile consistent with low-dose, once-monthly subcutaneous dosing -- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein the...
Omeros (OMER) announces preliminary results from the second cohort of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy.Narsoplimab is the company’s lead inhibitor of mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the ...
-- Study Patients Comprise Second Cohort from Bergamo, Italy -- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan...
Gainers: Big Rock Partners Acquisition (BRPA) +86%.Euro Tech Holdings (CLWT) +32%.Urban One (UONE) +28%.Sensei Biotherapeutics (SNSE) +28%.BBQ Holdings (BBQ) +22%.PDS Biotechnology (PDSB) +20%.Advanced Emissions Solutions (ADES) +19%.Progenity (PROG) +18%.Moxian (MOXC) +16%.Precipio (PRP...
Gainers: Precipio (PRPO) +23%, PDS Biotechnology (PDSB) +20%, Sensei Biotherapeutics (SNSE) +18%, Iovance Biotherapeutics (IOVA) +17%, Tyme Technologies (TYME) +12%.Losers: Black Diamond Therapeutics (BDTX) -30%, Aerpio Pharmaceuticals (A...
Omeros (OMER) announces that the U.S. FDA will require additional time to review the Biologics License Application ((BLA)) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.The health regulator has set an action date of October 17, 2...
-- PDUFA Date is October 17, 2021-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting infla...
Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at t...
Omeros Corp (OMER) Q1 2021 Earnings Conference Call May 10, 2021, 16:30 ET Company Participants Jennifer Williams - Investor Relations Gregory Demopulos - Co-Founder, Chairman, CEO & President Nadia Dac - Chief Commercial Officer Michael Jacobsen - CAO, VP, Finance & Treasurer Steven ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 09:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
$118.1 million, or 55%, of outstanding convertible notes due in 2026 repurchased at approximately 75% of notional value, resulting in $51 million in total debt extinguishment Repurchase funded from new $67 million secured four-year term loan maturing in June 2028 together with $21 million...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 419.5% to $0.24 on volume of 2,920,436,648 shares Greenwave Technology Solutions Inc. (GWAV) rose 147.7% to $0.1481 on volume of 1,864,631,229 shares Faraday Future Intelligent Electric Inc. (FF...